Objective: The incidence of certain non-AIDS-defining cancers (NADCs) in HIV patients has been reported to have increased in the combination antiretroviral therapy (ART) era. Studies are needed to directly evaluate the effect of ART use on cancer risk.
Introduction
Despite the overall success of combination antiretroviral therapy (ART) in treating HIV disease, HIV-infected persons continue to be at higher risk for developing AIDS-defining cancers (ADCs) and several types of non-ADCs (NADCs) when compared with the general population [1] [2] [3] [4] , even after adjusting for traditional cancer risk factors [5] . People with HIV are characterized by immunosuppression, chronic immune activation, and long-term exposure to antiretroviral agents. These factors have been speculated to mediate the increased cancer risk among HIV-infected persons [6] .
The most compelling evidence exists for an effect of immunodeficiency and cancer risk. A seminal metaanalysis by Grulich et al. [7] compared cancer risk in HIV/AIDS patients and organ transplant recipients, two populations that share few risk factors except for immunodeficiency. Cancers elevated in both populations included all those with a known or suspected viral causes, as well as lung, stomach, kidney, melanoma, multiple myeloma, and leukemia. A strong, direct relationship between lower CD4 cell count and increased risk for Kaposi sarcoma and non-Hodgkin lymphoma among HIV-infected persons is well established [8] [9] [10] . With regard to NADC, recent studies (including our own [5] ) have noted associations between low CD4 cell count and increased incidence of Hodgkin lymphoma [5, [11] [12] [13] [14] [15] , anal [5, 13, 14, 16, 17] , lung [5, [12] [13] [14] , and liver cancers [5, 13, 18] . In contrast, higher HIV RNA levels have been linked to higher risk for ADCs, but not NADCs [13, [19] [20] [21] .
The effect of ART use on cancer risk has also been studied, although most of these studies classified ART use as ever/never [22, 23] . Few studies have looked at individual NADCs and have adjusted for traditional cancer risk factors. Furthermore, although ART use overall has been associated with reduced risk of Kaposi sarcoma and non-Hodgkin lymphoma [4, 15, [24] [25] [26] , it is not known if part of the decreased incidence observed for ADCs and some NADCs in the ARTera are mediated by a direct effect of ART in addition to a broader indirect effect through better immune surveillance for malignancy. It has been suggested by experimental data that certain antiretroviral agents, such as protease inhibitors, may have anticarcinogenic properties including cell cycle arrest and cell death induction [27, 28] . These anticancer properties of antiretrovirals may, therefore, exert a direct protective effect on cancer development.
Additional research on the effects of ARTon cancer risk is needed to inform the development of clinical management and cancer screening guideline for people living with HIV infection. To address the gaps in the literature, we conducted a cohort study of 12 872 HIV-infected persons in Kaiser Permanente Northern (KPNC) and Southern California (KPSC) to examine the effects of ART therapy duration on risk of individual cancer types adjusting for traditional risk factors, and to explore whether there is any potential direct protective effect of antiretrovirals on carcinogenesis.
Methods

Study design, settings, and participants
We conducted a cohort study from 1996 to 2008 of adult HIV-infected individuals within KPNC and KPSC, both of which are large integrated healthcare delivery systems providing comprehensive medical care to more than 6.6 million members who are demographically representative of insured Californians [29] . HIV-infected individuals were identified from Kaiser Permanentemaintained HIV registries, which included all known cases of HIV infection dating back to the early 1980s for KPNC and to 2000 for KPSC. HIV-infected individuals were initially identified for inclusion in the registries by a positive HIV antibody test, quantifiable HIV RNA measurements, prescription of an HIV antiretroviral, HIV/AIDS-related diagnosis, or other evidence of HIV infection from electronic sources. Confirmation of cases was done by medical chart review and comparisons of case lists with Kaiser Permanente HIV clinics.
Eligible individuals for this study consisted of all adult (18 years of age) HIV-infected individuals who were Kaiser Permanente health plan members during the ART era. In addition, as our objective was to examine the effect of cumulative ART duration on the risk of cancer, we only included individuals for whom ART duration was known. Duration of ART could be established for all patients in KPNC, as the chart review completed at registry inclusion collected the date of first ART use, even if ART was initiated prior to Kaiser Permanente membership. In KPSC, as chart reviews did not capture the first ART date, we only included patients with at least 6 months prior Kaiser Permanente membership history with no ART.
The baseline date for analysis was assigned as the earliest date after 1996 (2000 for KPSC) when a member met all of the following criteria: 18 years of age, known to be HIV infected, and in HIV care, defined as the first recorded CD4 cell count measurement in the health system. Study participants were followed from baseline until the earliest of death, cancer diagnosis, health plan disenrollment, or 31 December 2008. The institutional review boards at KPNC and KPSC approved this study and provided waivers of informed consent.
Data sources
The primary data sources for this study were Kaiser Permanente's electronic medical records including HIV and cancer registries, pharmacy utilization, inpatient and outpatient diagnosis, laboratory records, administrative files, and mortality databases.
Outcome ascertainment
We identified incident cancers among our study cohort by record linkage with the KPNC and KPSC cancer registries, which are contributing sites to the Surveillance, Epidemiology, and End Results (SEER) program. Cancer case ascertainment is considered highly valid, as reporting of cancers to the California Cancer Registry and the National Cancer Institute SEER program is mandated under state law. The primary endpoints examined were incident ADC, infection-related NADC, and infectionunrelated NADC. ADC included Kaposi sarcoma, non-Hodgkin lymphoma, and invasive cervical cancer. For Kaposi sarcoma, outpatient diagnosis based on International Classification of Disease (ICD)-9th edition code 176.xx was also used to supplement data obtained from cancer registries for case identification. NADC included all cancers that are not ADC. A subset of NADC with known infectious cause were categorized as infection-related NADC [7, 30, 31] : these were vagina, vulva, penis, anal squamous cell, and certain oral cavity/pharynx squamous cell cancers defined by Chaturvedi et al. [31] , which are human papillomavirus (HPV) related; liver cancer that is hepatitis B and C-related; stomach cancer that is Helicobacter pylori related; and Hodgkin lymphoma that is Epstein-Barr virus related. All other NADCs were considered infection unrelated. In addition, we also considered the following individual cancer types that were among the most common cancers in HIV-infected persons, with at least 20 cases among ART users in our study population: Kaposi sarcoma, non-Hodgkin lymphoma, anal cancer (both squamous cell carcinoma and nonsquamous cell carcinoma), Hodgkin lymphoma, prostate, and lung cancer.
Assessment of combination antiretroviral therapy exposure
Use of antiretrovirals was ascertained using Kaiser Permanente's electronic pharmacy system, which included prescriptions dispensed at all Kaiser Permanente medical offices. Use of ART among HIV-infected individuals was defined as use of three or more antiretrovirals. ARTuse was examined as no ART use vs. any ART use and cumulative duration of any ART, protease inhibitors, and nonnucleotide reverse transcriptase inhibitors (NNRTIs). Cumulative therapy duration was calculated as the actual length of time covered by dispensed prescriptions, which inherently accounted for periods of nonadherence. Specifically, if a particular ARTwas discontinued, or there was a period of nonadherence, the duration variable was not updated until that therapy was started again.
Other covariates
Other factors considered as potential confounders included demographics (age, sex, race/ethnicity), HIV disease factors (pretreatment CD4 cell count and HIV RNA level, duration of known HIV infection, HIV transmission risk group, and prior exposure to single or dual antiretrovirals), and traditional cancer risk factors (alcohol/drug abuse, overweight/obesity, and tobacco use). Data on demographics and HIV disease factors were collected from HIV registries. Measurements of CD4 cell counts and HIV RNA levels were obtained from the Kaiser Permanente laboratory databases. CD4 cell count was modeled as a continuous variable. HIV RNA level was also modeled as a continuous variable and was logtransformed. Traditional cancer risk factors were assessed using Kaiser Permanente's inpatient and outpatient diagnosis and utilization files. Alcohol/drug abuse diagnoses were captured by ICD-9 codes 291, 292, 303-305.0, and 305.2-305.5 overweight or obesity diagnoses were captured by ICD-9 codes 278, 259.9, and V85 as well as Kaiser Permanente internal weight/height files and tobacco use was captured by ICD-9 codes 305.1, V15, V65, and 649, as well as Kaiser Permanente internal social history files.
Statistical analysis
The distribution of demographics and other potential confounders among the study cohort was calculated. Crude incidence as rate per 100 000 person-years was then computed for each cancer outcome of interest among person-time of no ART use and any ART use. Crude rate ratios for ART use status (no use vs. any use) were calculated using bivariate Poisson models. Adjusted rate ratios for any ART use in reference to no use as well as by duration of use were estimated by multivariable Poisson models adjusting for potential confounders. When the duration of protease inhibitor and NNRTI use were examined, protease inhibitor and NNRTI use were mutually adjusted in the model. P-value for test of linear trend was calculated.
To examine the overall effect of ART on cancer risk, we adjusted for pretreatment CD4 cell count and HIV RNA level. For person-time after ART initiation, the value of CD4 cell count and HIV RNA level was kept at the pretreatment value closest to treatment initiation. To examine the direct effect of ART on cancer development independent of ART's effect on CD4 cell count and HIV RNA level, CD4 cell count and HIV RNA level were adjusted as time-updated variables, that is, as recent CD4 cell count and HIV RNA level measured in the prior 6-month period in an alternative model.
We also performed several sensitivity analyses. First, cancer cases diagnosed within 6 months of study baseline were excluded to avoid the inclusion of potential prevalent cancer cases that should not be attributed to current ART use duration. A second sensitivity analysis replaced pretreatment CD4 with nadir CD4 (i.e. lowest recorded in Kaiser Permanente) to further clarify observed associations of cancer risk with ART use. Finally, for anal cancer, given the potential for strong confounding by sexual orientation, we also conducted stratified analysis for MSM and other males. There were no female anal cancer cases identified, precluding a stratified analysis in this group. All analyses were performed with SAS (version 9.1; SAS Institute Inc., Cary, North Carolina, USA), using procGENMOD for Poisson regression.
Results
A total of 12 872 HIV-infected individuals with complete data on antiretroviral use were included in the study. The mean age of the study population was 40 years (Table 1) . Ninety percent of the study participants were male, and approximately half (44%) were racial/ethnic minorities. The majority of the participants were MSM (62%). Of all participants, 21% were exposed to single and/or dual antiretrovirals prior to study baseline. Mean CD4 cell count at study baseline was 364 cells/ml. Table 2 shows the crude incidence rates of the cancers of interest by ART use status. Kaposi sarcoma and non-Hodgkin lymphoma were the most commonly diagnosed cancers, regardless of ART use status. For NADC, anal cancer was the most commonly diagnosed NADC among person-time exposed to ART. On the contrary, lung cancer was the most commonly diagnosed cancer among person-time not exposed to ART, followed by prostate cancer ( Table 2 ). In the unadjusted analyses, ART use was significantly associated with a lower rate of ADC, yet, a higher rate of infection-related NADCs, largely driven by anal cancer ( Table 2) .
AIDS-defining cancer
In the multivariable analyses examining any ART use vs. no use, overall ART use remained strongly associated with lower incidence of ADC. This association was diminished when recent CD4 cell count and HIV RNA level were included in the model (Table 3 ).
In the multivariable analyses examining duration of overall ART, protease inhibitor, and NNRTI use, the longer the duration of overall ART/protease inhibitor/ NNRTI use, the lower the incidence of Kaposi sarcoma and non-Hodgkin lymphoma. These inverse associations with Kaposi sarcoma were observed both with adjustment of pretreatment CD4 cell count and HIV RNA level [rate ratio per year increase ART ¼ 0.54 (95% confidence interval 0.47-0.61), P-value for trend < 0.01] ( (Table 5) .
Non-AIDS-defining cancer
In the multivariable analyses examining any ART use vs. no use, overall ART use was associated with lower risk of noninfection-related NADC ( Table 3 ). In the model adjusting for recent CD4 cell count and HIV RNA, overall ART use was associated with a lower incidence of prostate cancer [rate ratio ¼ 0.34 (0.15-0.78), Table 3 ].
In the multivariable analyses examining duration of overall ART, protease inhibitor, and NNRTI use, no clear dose-response relationship with overall ART, protease inhibitor, or NNRTI use duration was seen for NADC, infection-related or infection-unrelated, anal cancer, lung cancer, prostate cancer, or Hodgkin lymphoma, when pretreatment CD4 cell count and HIV RNA level were adjusted for in the model ( Finally, sensitivity analyses that excluded the first 6 months of follow-up for all participants resulted in similar results, suggesting the inclusion of potentially prevalent cancers was not a significant issue. 
Discussion
We found that the association between ART use and reduced risk ADC appeared to be mediated in part by ART's effect on CD4 cell count and HIV RNA level, but not completely. Our results suggest that ART might have a direct protective effect on ADC, independent of ART's effect in increasing CD4 cell count. We found similar effects of protease inhibitor and NNRTI on Kaposi sarcoma and non-Hodgkin lymphoma, suggesting lack of a therapy class effect on risk of ADC. In addition, we also observed an increased risk of anal cancer with increased duration of overall ART or protease inhibitor use. On the contrary, an inverse association was found for duration of overall ART or protease inhibitor use and risk of prostate cancer.
The finding that overall ART use was associated with reduced risk of Kaposi sarcoma and non-Hodgkin lymphoma upon adjusting for recent CD4 cell count and HIV RNA level suggests that antiretrovirals may confer additional anticancer benefits other than maintaining immune function. Protease inhibitor agents have been shown to confer a broad spectrum of anticancer properties. In experimental studies, the observed anticancer mechanisms included inhibition of phosphoinositide 3-kinase/protein kinase B pathway, induction of caspase-dependent apoptosis and caspase-independent cell death through induction of endoplasmic reticulum stress and autophagy [32, 33] . In addition to direct cytotoxicity, some protease inhibitor drugs also demonstrate the ability to induce cell cycle arrest [34] . The antiproliferation and cell death induction effects of protease inhibitor agents have been shown in a large number of cell lines of several types of cancer, both in vitro and in vivo [33] . NNRTI agents also demonstrate anticancer effects in experimental models. NNRTI inhibits endogenous reverse transcriptase encoded by long interspersed nuclear element-1 and human endogenous retroviruses by binding to the reserve transcriptase protein and inducing a conformational change resulting in reduced enzyme activity. The downstream effects are reduced cell growth and induced differentiation, as shown in cancer cell line and murine cancer models [28, 35, 36] . Additional epidemiologic and laboratory data will be needed before a causal, direct effect of ART, independent of CD4 cell count and HIV viral replication, can be confirmed.
The effect of ART use on the risk of NADC has been controversial in the literature. Although some studies reported a protective effect of ART use on risk of NADC [13, 19, 37] , others reported an adverse association (mainly between NNRTI users and risk of Hodgkin lymphoma) [17] or no association [15, 38] . The conflicting results may be due to limitations in study methods that masked the variation in study population in terms of ARTuse history, baseline risk of cancer, and so on. For example, most of these studies defined ART use as a binary variable for use vs. no use, and did not examine any dose-response relationship with duration of use, or agent-specific effects. Furthermore, the number of overall NADC was too low to conduct cancer type-specific analysis. Guiguet et al. have examined ART duration (6 or >6 months) and risk of individual cancer types identified by ICD-9 codes using the French Hospital Database. They did not find ART use to be a predictor of risk for several NADC, including anal, lung, liver cancer, and Hodgkin lymphoma [13] . On the contrary, ADC, NADC grouped by infection-related vs. not, or prostate cancer were not examined in this study. In the present study, with a relatively large number of ADC and NADC cases, we further examined the effects of duration of use, ART therapy class, and by individual cancer type. We did not find clear association between ART use and risk of NADC, infection-related or infection-unrelated, lung cancer or Hodgkin lymphoma.
An increased anal cancer risk was observed for long term use of ART, particularly protease inhibitor therapy. This finding is somewhat consistent with calendar trends of anal cancer incidence reported by others [16, 39, 40] . Among those who examined risk factors for anal cancer among HIV-infected persons, Piketty et al. also reported an increased anal cancer risk in ART users [16] . Powles et al. on the contrary, reported lack of association between ARTuse and risk of anal cancer [17] . It is unclear what the potential underlying biological mechanism is for the observed association of anal cancer and protease inhibitor therapy. In fact there are some alternative explanations. For instance, the higher cancer risk with longer duration ART use may be explained by prolonged exposure to HPV, the causative agent of anal cancer; however, our analyses did adjust for known years of HIV infection. Alternatively, more vigilant screening for anal cancer among those on ART might explain the higher risk among ART users. However, the ART class effect observed here argues against both explanations. Another possibility is residual confounding by sexual orientation, as MSM have a known increased risk of anal cancer, and MSM may also contribute the longest duration of protease inhibitors. However, multivariable models did adjust for HIV risk, and sensitivity analyses indicated similar results by ART class for MSM and other men. Despite these assurances, confounding cannot be ruled out, as we did not have information on sexual practices, such as having unprotected anal sex.
The other cancer identified to be associated with ART was prostate cancer, with decreased rates with long-term ART use, specifically protease inhibitor use. This inverse association was only observed in models that adjusted for recent CD4 cell count and HIV RNA levels. Thus, if the association is causal, this suggests that protease inhibitors protect against prostate cancer through a mechanism not mediated by CD4 and/or HIV RNA. This is notable given the observed decreased risk of prostate cancer among HIV patients we and others have reported previously. Although the reason for the decreased risk is unknown, some have suggested it is due to reduced prostate-specific antigen screening [41] . Preliminary data from our group, however, suggests HIV patients are more vigilantly screened for prostate cancer [42] . Our results suggest a direct protective effect of protease inhibitors, consistent with in-vivo and in-vitro studies demonstrating antitumor effects for protease inhibitors on prostate cancer cells [43, 44] .
Some potential limitations in our study should be considered when interpreting the results. First, our measurement for certain cancer risk factors, such as tobacco use, alcohol/drug abuse, and overweight/obesity, were based on documentation in the electronic medical records rather than direct patient survey. For cancers in which routine screening procedures exist, such as prostate cancer and colorectal cancer, we did not take into account the screening behavior that may vary between ART use subgroups. However, there is little reason to suspect differential cancer screening behaviors between ART use subgroups (e.g. protease inhibitor or NNRTI). On the contrary, it is possible that ART users may be more attentive to cancer screening than non-ART users. This, however, would not explain the reduced prostate cancer risk observed with ARTuse. An additional limitation was the focus on overall ART and ART class effects. Followup studies focusing on individual ART medications, or first-line vs. second-line ART, may be further informative. In addition, it should be noted that our results have limited generalizability to women, as women made up only 10% of the cohort. Lastly, adjusting for recent CD4 and HIV RNA in the multivariable model using standard approaches may bias the results, if there is an unadjusted factor that is both causally related to CD4/HIV RNA, and itself modifies cancer risk [45] . However, we are not aware of any other such factors that are not included in our model to cause significant bias through this manner.
Despite these limitations, our study has several important strengths. As described earlier, our study addresses several major gaps in the literature on this topic by examining class-specific effect, dose-response relationship by duration of use, and cancer type-specific analysis. In addition, this study was based on a well defined, large populationbased cohort of HIV-infected individuals with complete information on antiretroviral use history. The ascertainment of HIV status, cancer diagnosis, and ART use was highly valid with the collection of data from disease registries and pharmacy databases. We found that the protective effect of ART on ADC does not vary by therapy class. Thus, we did not find evidence in support of ART regimen choices, such as protease inhibitor-based ART, to reduce the burden of ADC. Our findings also suggested a potentially adverse effect of long-term use of protease inhibitors on anal cancer, and a protective effect for prostate cancer. Given the lack of known biological plausibility, these findings require further confirmation by other studies. Nevertheless, given the lifelong commitment to ART and the long cancer induction period, continued evaluation of cancer risk in this population is needed.
